Drug Profile
Lassomycin - NovoBiotic Pharmaceuticals
Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Northeastern University
- Developer Northeastern University; NovoBiotic Pharmaceuticals
- Class Anti-infectives; Antituberculars; Peptides
- Mechanism of Action Endopeptidase Clp inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Tuberculosis
Most Recent Events
- 04 Sep 2023 Lassomycin is still in preclinical trials for Tuberculosis in USA (NovoBiotic Pharmaceuticals pipeline, September 2023)
- 28 May 2018 No recent reports of development identified for preclinical development in Tuberculosis in USA
- 24 Apr 2014 Preclinical trials in Tuberculosis in USA (unspecified route) before April 2014